Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Toxicities Associated with Tyrosine Kinase Inhibitor Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2023-187460

Published: 2023

Journal Articles

Single Center Retrospective Study of Midostaurin Plus Intensive Chemotherapy for Older Patients with Newly Diagnosed FLT-3 Mutated Acute Myelogenous Leukemia

Blood (2023) 142 (Supplement 1): 5937.

https://doi.org/10.1182/blood-2023-173978

Published: 2023

Journal Articles

Slow and Steady Wins the Race: Optimization of Older Adult Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Candidates

Sarah A Wall, Allesia Funderburg, Nowshin Islam, Ying Huang, Edmund Folefac, Carolyn Presley, Erin Stevens, Andrew Artz, Ashley E Rosko

Blood (2023) 142 (Supplement 1): 2432.

https://doi.org/10.1182/blood-2023-188796

Published: 2023

Journal Articles

Outcomes of Patients Undergoing Fludarabine and Melphalan-Based Conditioning with Post-Transplant Cyclophosphamide for Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplant: Donor Type Effect

Blood (2023) 142 (Supplement 1): 2151.

https://doi.org/10.1182/blood-2023-187687

Published: 2023

Journal Articles

Final Results from Phase 1 Study of Briquilimab, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myeloid Leukemia in Complete Remission and Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation

Arpita Gandhi, Andrew Artz, Catherine J. Lee, Ankur Varma, Bart L. Scott, Hye-Sook Kwon, Minyoung Youn, Chikako Yanagiba, Jeyakavitha Arulprakasam, Anne Le, Judith Shizuru, Wendy W Pang, Lori S. Muffly

Blood (2023) 142 (Supplement 1): 470.

https://doi.org/10.1182/blood-2023-185533

Published: 2023

Journal Articles

Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

Blood (2023) 142 (Supplement 1): 4981.

https://doi.org/10.1182/blood-2023-182058

Published: 2023

Journal Articles

Combined Cytokine Blocking Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft Versus Host Disease (SR-GvHD)

Blood (2023) 142 (Supplement 1): 4944.

https://doi.org/10.1182/blood-2023-190808

Published: 2023

Journal Articles

A Phase 1 Study of Venetoclax in Combination with a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed Adults with B-Cell Ph-like ALL

Blood (2023) 142 (Supplement 1): 2870.

https://doi.org/10.1182/blood-2023-187469

Published: 2023

Journal Articles

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Blood (2023) 142 (Supplement 1): 109.

https://doi.org/10.1182/blood-2023-173855

Published: 2023

Journal Articles

Favorable Survival Outcomes in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Fludarabine/Melphalan-Conditioning with Tacrolimus/Sirolimus-Based Gvhd Prophylaxis

Blood (2023) 142 (Supplement 1): 4959.

https://doi.org/10.1182/blood-2023-187156

Published: 2023

Journal Articles

Fractionated Total Body Irradiation and Fludarabine Based Conditioning Regimen with Post-Transplant Cyclophosphamide (PTCy) for Mismatched Related and Unrelated Donors HCT for Acute Leukemia and MDS

Blood (2023) 142 (Supplement 1): 3537.

https://doi.org/10.1182/blood-2023-187728

Published: 2023

Journal Articles

Improving Outcomes of Peripheral Blood Stem Cell (PBSC) HLA-Mismatched Unrelated Donor (MMUD) Hematopoietic Cell Transplantation (HCT): Effect of Graft Versus Host Disease (GVHD) Prophylaxis

Blood (2023) 142 (Supplement 1): 4896.

https://doi.org/10.1182/blood-2023-187909

Published: 2023

Journal Articles

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases

Monica S. Thakar, Larisa Broglie, Brent Logan, Andrew Artz, Nancy Bunin, Lauri M. Burroughs, Caitrin Fretham, David A. Jacobsohn, Alison W. Loren, Joanne Kurtzberg, Caridad A. Martinez, Shin Mineishi, Adam S. Nelson, Ann Woolfrey, Marcelo C. Pasquini, Mohamed L. Sorror

Blood (2019) 133 (7): 754–762.

https://doi.org/10.1182/blood-2018-09-876284

Published: 2019

Includes: Supplemental data

Journal Articles

Fludarabine Melphalan Conditioning Followed By T-Replete Haplo Identical (Haplo) Transplantation or Haplo Cord (HC) Transplantation

Koen Van Besien, MD PhD, Andrew Artz, MD, Richard E Champlin, MD, Danielle Guarneri, Michael R. Bishop, MD, Julianne Chen, Tsiporah B. Shore, MD, Hongtao Liu, MD PhD, Gabriela Rondon, MD, Sebastian A. Mayer, MD, Stefan O. Ciurea

Blood (2017) 130 (Supplement 1): 3328.

https://doi.org/10.1182/blood.V130.Suppl_1.3328.3328

Published: 2017

Journal Articles

The Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Transplantation

Claudio G Brunstein, MD PhD, Marcelo C. Pasquini, MDMS, Soyoung Kim, Mingwei Fei, MS, Andrew Artz, MD, Minoo Battiwalla, MD, Nelli Bejanyan, MD, Robert Peter Gale, MD ScD, PhD, Peiman Hematti, MD, Oscar Boutros Lahoud, MD, Marcos De Lima, MD, Ran Reshef, MD, Seth J Rotz, MD, Bipin N. Savani, MD, Harry C. Schouten, MD, Shin Mineishi, MD, John Rogosheske, PharmD, Miguel-Angel Perales, MD

Blood (2017) 130 (Supplement 1): 3292.

https://doi.org/10.1182/blood.V130.Suppl_1.3292.3292

Published: 2017

Journal Articles

Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Hongtao Liu, MD PhD, Andrew Artz, MD, Richard A. Larson, MD, Satyajit Kosuri, MD, Wendy Stock, MD, Michael R. Bishop, MD

Blood (2017) 130 (Supplement 1): 3312.

https://doi.org/10.1182/blood.V130.Suppl_1.3312.3312

Published: 2017

Journal Articles

Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS

Kothari Shawn, MD, Andrew Artz, MD, Sang Mee Lee, PhD, Noreen Fulton, BS, Jae-Hyun Park, Wendy Stock, MD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Justin Kline, MD, Lucy Godley, MD PhD, James LaBelle, MD PhD, Satyajit Kosuri, MD, Peter A Riedell, MD, Yusuke Nakamura, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2017) 130 (Supplement 1): 4572.

https://doi.org/10.1182/blood.V130.Suppl_1.4572.4572

Published: 2017

Journal Articles

Validation of Pre-Transplant Biomarker Measurement and Risk Score for Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant (HCT)

Michael J. Leukam, MD, Lucy Godley, MD PhD, Justin Kline, MD, Richard A. Larson, MD, Hongtao Liu, MD PhD, Olatoyosi Odenike, MD, Wendy Stock, MD, Michael R. Bishop, MD, Andrew Artz, MD

Blood (2017) 130 (Supplement 1): 4558.

https://doi.org/10.1182/blood.V130.Suppl_1.4558.4558

Published: 2017

Journal Articles

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Blood (2017) 130 (9): 1156–1164.

https://doi.org/10.1182/blood-2017-03-772368

Published: 2017

Includes: Supplemental data

Journal Articles

Excellent Clinical Outcome for Relapsed and Refractory Lymphoma Patients with Haplo-Cord Allogeneic Stem Cell Transplantation

Jingmei Hsu, MD PhD, Andrew Artz, MD MS, Sebastian A. Mayer, MD, Michael R. Bishop, MD, Adrienne A. Phillips, MD MPH, Sonali M. Smith, MD, Usama Gergis, MD, Justin Kline, MD, Tsiporah B. Shore, MD, Koen van Besien, MD

Blood (2016) 128 (22): 3496.

https://doi.org/10.1182/blood.V128.22.3496.3496

Published: 2016

NARROW

Toxicities Associated with Tyrosine Kinase Inhibitor Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Single Center Retrospective Study of Midostaurin Plus Intensive Chemotherapy for Older Patients with Newly Diagnosed FLT-3 Mutated Acute Myelogenous Leukemia

Slow and Steady Wins the Race: Optimization of Older Adult Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Candidates

Outcomes of Patients Undergoing Fludarabine and Melphalan-Based Conditioning with Post-Transplant Cyclophosphamide for Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplant: Donor Type Effect

Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

Combined Cytokine Blocking Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft Versus Host Disease (SR-GvHD)

A Phase 1 Study of Venetoclax in Combination with a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed Adults with B-Cell Ph-like ALL

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Favorable Survival Outcomes in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Fludarabine/Melphalan-Conditioning with Tacrolimus/Sirolimus-Based Gvhd Prophylaxis

Fractionated Total Body Irradiation and Fludarabine Based Conditioning Regimen with Post-Transplant Cyclophosphamide (PTCy) for Mismatched Related and Unrelated Donors HCT for Acute Leukemia and MDS

Improving Outcomes of Peripheral Blood Stem Cell (PBSC) HLA-Mismatched Unrelated Donor (MMUD) Hematopoietic Cell Transplantation (HCT): Effect of Graft Versus Host Disease (GVHD) Prophylaxis

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases

Fludarabine Melphalan Conditioning Followed By T-Replete Haplo Identical (Haplo) Transplantation or Haplo Cord (HC) Transplantation

The Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Transplantation

Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS

Validation of Pre-Transplant Biomarker Measurement and Risk Score for Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant (HCT)

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Excellent Clinical Outcome for Relapsed and Refractory Lymphoma Patients with Haplo-Cord Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only